Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 15;12:9795–9807. doi: 10.2147/OTT.S219440

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

MiR-618 upregulation impairs OS tumor growth in vivo. (A) Representative images of tumor xenografts derived from HOS cells transfected with the miR-618 mimics or miR-NC. (B) The volume of tumor xenografts in the miR-618 mimic group was smaller than that in the miR-NC group. *P < 0.05 compared with group miR-NC. (C) Tumor xenografts in the miR‐618 mimic group and miR-NC group were excised and weighed at 4 weeks after implantation. *P < 0.05 vs miR-NC. (D) RT-qPCR was performed to analyze miR-618 expression in the tumor xenografts. *P < 0.05 vs group miR-NC. (E) Protein amounts of MTDH, PTEN, p-AKT, and AKT in tumor xenografts were quantified by Western blotting.